Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
December 3, 2024 | HTA, Health Technology Assessments, ISPOR Europe, Payers, RWE, ispor, payer insights, real-world evidence
Genesis Research Group’s poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey’ was recently named as ‘Best General Poster Research Presentation’ for ISPOR Europe 2024.
Along with other Genesis Research Group presentations, the poster has recently been featured by The Evidence Base in an interview entitled ‘Payer Perspectives on Key Challenges in Healthcare Decision-Making: actionable insights for life sciences companies’.
Prior to being awarded ‘Best General Poster Research Presentation‘ for ISPOR Europe 2024, authors of the poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey‘ were interviewed by The Evidence Base alongside other Genesis Research Group authors.
Payer perspectives are essential in ensuring that new treatments demonstrate not only clinical efficacy but also cost-effectiveness, while aligning with the priorities and sustainability of healthcare systems. For life sciences companies, understanding payer approaches to the complex challenges of reimbursement decision-making—including budget impact assessments, cost-effectiveness analyses, and evaluations of clinical value—is critical for shaping patient access to innovative therapies and informing healthcare policy.
In this interview, The Evidence Base spoke with Tijana Ignjatovic, Darrin Benjumea, and Manica Agrawal about new research that focuses on gathering payer perspectives on these key issues in healthcare. The survey results were recently presented at ISPOR Europe 2024 (November 17–20, 2024, Barcelona, Spain).
Darren Benjumea was the co-author and presenter of the previously mentioned ISPOR Europe winning poster, the additional authors being Tijana Ignjatovic, Alice Jackson, Kristen Downs, and Lynn Okamoto.
Congratulations to the Genesis Research Group team!
You can read the article online or contact Genesis Research Group at solutions@genesisrg.com if you’d like a copy of the poster.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will…
On GLOBE Final Rule
The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally….
Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.
On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…